

QIBA SPECT Biomarker Committee (BC)

Friday, August 21, 2015, 9 AM (CT)

Call Summary

Amended 9/30/2015

In attendance:

Yuni Dewaraja, PhD (Co-Chair)
P. David Mozley, MD (Co-Chair)
John Seibyl, MD (Co-Chair)
John Dickson, PhD
Hidehiro Iida, DSc, PhD
Michael A. King, PhD, DABR

Gregory Klein, PhD
Gil Kovalski, PhD
Michael Lassmann, PhD
Robert Miyaoka, PhD
Nancy Obuchowski, PhD
Eric Perlman, MD

Anne Smith, PhD
John Sunderland, PhD
Zsolt Szabo, MD, PhD
Benjamin M. W. Tsui, PhD
Brian Zimmerman, PhD

RSNA

Joe Koudelik
Julie Lisiecki

Moderator: Dr. Seibyl

Discussion Topics

- Literature search continues to determine appropriate common measurands and use case
 - 95% of the papers reviewed in the literature search discuss use of the ratio measure (SPR – 1)
- Ad hoc Work Groups will be formed with team members of similar expertise to begin work on segments of the draft Profile
 - Work Groups may eventually be asked to host their own WebEx calls depending on availability of RSNA Staff
- Questions raised regarding the following:
 - How phantoms will be used to meet tumor and striatal measurements
 - Which radionuclides will be the focus of the Profile
 - It was decided to minimize complexity by focusing on I-123 in the brain
 - Work with Technetium in the body to continue at approximately ½ step behind the I-123 Profile
 - Type of claim to pursue: longitudinal vs. cross-sectional
 - Group to start with exploration of cross-sectional claim with focus on I-123 in the brain
- Drs. Dickson and Klein volunteered to collaborate on a bulleted outline for I-123 in the brain prior to the next SPECT call on September 18th
 - They will provide the outline to co-chairs for review prior to distribution to the group
- Suggestions for other work group topics included the following:
 - Protocol development
 - subject prep
 - imaging of the subject
 - flow of the imaging process
 - Site qualification
 - highly dependent on phantom design
- A Profile template is available on the [QIBA Wiki](#) under the heading: *Claim and Profile Template Documents*
 - Dr. Obuchowski also provided an overview of a flow chart aide to determine claims

Upcoming Nuclear Medicine Calls (Fridays, 9 am CT):

- **August 28:** **Combined Nuclear Medicine BCs** (FDG-PET, Amyloid, SPECT)
- **Sept 4:** FDG-PET Biomarker Ctte
- **Sept 11:** Amyloid Biomarker Ctte
- **Sept 18:** SPECT Biomarker Ctte
- **Sept 25:** **Combined Nuclear Medicine BCs** (FDG-PET, Amyloid, SPECT)

RSNA Staff attempt to identify and capture all committee members participating on WebEx calls. However, if multiple callers join simultaneously or call in without logging on to the WebEx, identification is not possible. Call participants are welcome to contact RSNA staff at QIBA@RSNA.org if their attendance is not reflected on the call summaries. [QIBA wiki](#)